

Accepted Manuscript

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor


Anthony B. Pinkerton, Eduard Sergienko, Yalda Bravo, Russell Dahl, Chen-Ting Ma, Qing Sun, Michael R. Jackson, Nicholas D.P. Cosford, José Luis Millán

PII: S0960-894X(17)31110-1
DOI: <https://doi.org/10.1016/j.bmcl.2017.11.024>
Reference: BMCL 25430

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 16 October 2017
Revised Date: 9 November 2017
Accepted Date: 10 November 2017

Please cite this article as: Pinkerton, A.B., Sergienko, E., Bravo, Y., Dahl, R., Ma, C-T., Sun, Q., Jackson, M.R., Cosford, N.D.P., Millán, J.L., Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: <https://doi.org/10.1016/j.bmcl.2017.11.024>



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor

Anthony B. Pinkerton^{1,*}, Eduard Sergienko¹, Yalda Bravo¹, Russell Dahl¹, Chen-Ting Ma¹, Qing Sun¹, Michael R. Jackson¹, Nicholas D. P. Cosford², and José Luis Millán³

¹Conrad Prebys Center for Chemical Genomics, ²NCI Designated Cancer Center, ³Sanford Children's Health Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA

This is where the receipt/accepted dates will go; Received Month XX, 2017; Accepted Month XX, 2017 [BMCL RECEIPT]

Abstract— Tissue-nonspecific alkaline phosphatase (TNAP) is an ectoenzyme crucial for bone matrix mineralization via its ability to hydrolyze extracellular inorganic pyrophosphate (ePP_i), a potent mineralization inhibitor, to phosphate (P_i). By the controlled hydrolysis of ePP_i, TNAP maintains the correct ratio of P_i to ePP_i and therefore enables normal skeletal and dental calcification. In other areas of the body low ePP_i levels lead to the development of pathological soft-tissue calcification, which can progress to a number of disorders. TNAP inhibitors have been shown to prevent these processes via an increase of ePP_i. Herein we describe the use of a whole blood assay to optimize a previously described series of TNAP inhibitors resulting in 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent, selective and oral bioavailable compound that robustly inhibits TNAP *in vivo*.

*To whom correspondence should be addressed. Tel. +1-858-795-5320. E-mail: apinkerton@sbpdiscovery.org

Download English Version:

<https://daneshyari.com/en/article/7780318>

Download Persian Version:

<https://daneshyari.com/article/7780318>

[Daneshyari.com](https://daneshyari.com)